For men with metastatic prostate cancer, understanding ones prostate specific antigen (PSA) kinetics is important. Despite the issues we hear surrounding the PSA, it is still the best measure you have in aiding you in the assessing your possible outcome prognosis. PSA kinetics also are a potential surrogate marker for clinical trial results. In most [...]
Teva Pharmaceutical Industries has received approval and launched, in the United States, a generic version of the Avodart (dutasteride) capsules at the 0.5 mg dose. Avodart, 5-alpha reductase inhibitor, is FDA approved for the treatment of men with benign prostate hyperplasia (an enlarged prostate gland), however, although not approved; men often use it as a [...]
There are many trials and tribulations facing new drug approvals for men with prostate cancer. This is particularly true for men the drugs that are designed to fight metastatic castration-resistant prostate cancer (mCRPC) because of the many new treatments, all with life extending ability, that we now have available to use. The good news is [...]
I stumbled upon a fascinating piece of research from Iceland that looked at the role of Circadian Disruption in Prostate Cancer Development. Knowing my own very poor sleeping patterns and having heard many other men with advanced prostate cancer complaining about very similar experiences it peaked my interest. The researchers pointed out that there have [...]
It is commonly known that our current clinical trials struggle to enroll adequate numbers of minority men. Our inability to enroll a cross section of men that truly reflects the general population in prostate cancer clinical trials means that our results might not accurately reflect the best information for a minority man. The lack of [...]